ApoL1 levels in high density lipoprotein and cardiovascular event presentation in patients with familial hypercholesterolemia
Cubedo, Judit (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Padró, Teresa (Institut d'Investigació Biomèdica Sant Pau)
Alonso, Rodrigo (Jimenez Diaz Foundation)
Mata, Pedro (Fundación Hipercolesterolemia Familiar)
Badimon, Lina (Institut d'Investigació Biomèdica Sant Pau)
Universitat Autònoma de Barcelona

Data:	2016
Resum:	HDL composition rather than HDL-cholesterol (HDL-C) levels seems to be a key determinant of HDL-induced atheroprotection. Heterozygous familial hypercholesterolemia (FH) patients, with lifelong exposure to high LDL levels, show a high prevalence of premature coronary artery disease. We hypothesized that HDL of FH patients might have a modified protein composition and investigated the proteomic signature of HDL obtained from FH patients and their unaffected relatives. HDLs were characterized by 2D electrophoresis/MS in 10 families from the SAFEHEART cohort (3 individuals/family: 2 with genetic FH diagnosis and 1 non-FH relative) clinically characterized and treated as per guidelines. FH patients had lower apoA-I levels and a differential HDL distribution profile of apoL1 and apoA-IV. ELISA validation revealed decreased apoL1 serum levels in FH patients. ApoL1 levels were able to predict presentation of an ischemic cardiac event, and apoL1/HDL-C ratio was associated with the survival rate after the event. FH patients who died because of a fatal cardiac event had lower apoL1 and LCAT content in HDL3 an average of 3. 5 years before the event than those who survived. Changes in HDL protein composition could affect patients prognosis. The proteomic profile of apoL1 is modified in HDLs of high cardiovascular risk patients, and apoL1 plasma levels are significantly lower in serum and in HDL3 of patients that will suffer an adverse cardiac event within 3 years. Cubedo, J. , T. Padr, R. Alonso, P. Mata, and L. Badimon. ApoL1 levels in high density lipoprotein and cardiovascular event presentation in patients with familial hypercholesterolemia.
Ajuts:	Ministerio de Economía y Competitividad RD12/0042/0027 Ministerio de Economía y Competitividad RD12/0019/0026 Ministerio de Economía y Competitividad SAF2013-42962-R Ministerio de Economía y Competitividad PI13/02850
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Apolipoprotein L1 ; Biomarkers ; Mortality ; Prognosis ; Proteomics
Publicat a:	Journal of Lipid Research, Vol. 57 Núm. 6 (june 2016) , p. 1059-1073, ISSN 1539-7262

DOI: 10.1194/jlr.P061598
PMID: 27112635

15 p, 1.5 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats